Cargando…
Enhanced In Vivo Activity of Cefditoren in Pre-Immunized Mice against Penicillin-Resistant S. pneumoniae (Serotypes 6B, 19F and 23F) in a Sepsis Model
BACKGROUND: Specific antibodies are likely to be present before S. pneumoniae infection. We explored cefditoren (CDN) total and free values of serum concentrations exceeding the MIC (t>MIC) related to efficacy in a mice sepsis model, and the effect of specific gammaglobulins on in-vitro phagocyto...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919394/ https://www.ncbi.nlm.nih.gov/pubmed/20706584 http://dx.doi.org/10.1371/journal.pone.0012041 |
_version_ | 1782185174839066624 |
---|---|
author | Cafini, Fabio Yuste, Jose Giménez, Maria-Jose Sevillano, David Aguilar, Lorenzo Alou, Luis Ramos-Sevillano, Elisa Torrico, Martha González, Natalia García, Ernesto Coronel, Pilar Prieto, Jose |
author_facet | Cafini, Fabio Yuste, Jose Giménez, Maria-Jose Sevillano, David Aguilar, Lorenzo Alou, Luis Ramos-Sevillano, Elisa Torrico, Martha González, Natalia García, Ernesto Coronel, Pilar Prieto, Jose |
author_sort | Cafini, Fabio |
collection | PubMed |
description | BACKGROUND: Specific antibodies are likely to be present before S. pneumoniae infection. We explored cefditoren (CDN) total and free values of serum concentrations exceeding the MIC (t>MIC) related to efficacy in a mice sepsis model, and the effect of specific gammaglobulins on in-vitro phagocytosis and in-vivo efficacy. METHODOLOGY/PRINCIPAL FINDINGS: We used three pneumococcal isolates (serotype, MIC of CDN): Strain 1 (6B, 1 µg/ml), Strain 2 (19F, 2 µg/ml) and Strain 3 (23F, 4 µg/ml). Hyperimmune serum (HS) was obtained from mice immunized with heat-inactivated strains. In-vitro, phagocytosis by HS diluted 1/10 in presence/absence of sub-inhibitory concentrations was measured by flow cytometry including fluorescent bacteria and a neutrophil cell line. In-vivo dose-ranging experiments with HS (dilutions 1/2–1/16) and CDN (6.25 mg/kg–100 mg/kg tid for 48 h) were performed to determine the minimal protective dilution/dose (highest survival) and the non-protective highest dilution/dose (highest mortality: HS-np dilution and CDN-np dose) over 7 days. Efficacy of CDN-np in animals pre-immunized with HS-np (combined strategy) was explored and blood bacterial clearance determined. The CDN measured protein binding was 86.9%. In-vitro, CDN significantly increased phagocytosis (vs. HS 1/10). In non pre-immunized animals, t>MIC values for CDN of ≈35% (total) and ≈19% (free) were associated with 100% survival. Significant differences in survival were found between HS-np alone (≤20%) or CDN-np alone (≤20%) vs. the combined strategy (90%, 60% and 60% for Stains 1, 2 and 3), with t>MIC (total/free) of 22.8%/14.3%, 26.8%/16.0%, and 22.4%/12.7% for Strains 1, 2 and 3, respectively. Prior to the second dose (8 h), median bacterial counts were significantly lower in animals surviving vs. dead at day 7. CONCLUSIONS/SIGNIFICANCE: In mice (CDN protein binding similar to humans) total t>MIC values of ≈35% (≈19% free) were efficacious, with a decrease in the required values in pre-immunized animals. This reinforces that immunoprotection to overcome resistance may provide lifesaving strategies. |
format | Text |
id | pubmed-2919394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-29193942010-08-12 Enhanced In Vivo Activity of Cefditoren in Pre-Immunized Mice against Penicillin-Resistant S. pneumoniae (Serotypes 6B, 19F and 23F) in a Sepsis Model Cafini, Fabio Yuste, Jose Giménez, Maria-Jose Sevillano, David Aguilar, Lorenzo Alou, Luis Ramos-Sevillano, Elisa Torrico, Martha González, Natalia García, Ernesto Coronel, Pilar Prieto, Jose PLoS One Research Article BACKGROUND: Specific antibodies are likely to be present before S. pneumoniae infection. We explored cefditoren (CDN) total and free values of serum concentrations exceeding the MIC (t>MIC) related to efficacy in a mice sepsis model, and the effect of specific gammaglobulins on in-vitro phagocytosis and in-vivo efficacy. METHODOLOGY/PRINCIPAL FINDINGS: We used three pneumococcal isolates (serotype, MIC of CDN): Strain 1 (6B, 1 µg/ml), Strain 2 (19F, 2 µg/ml) and Strain 3 (23F, 4 µg/ml). Hyperimmune serum (HS) was obtained from mice immunized with heat-inactivated strains. In-vitro, phagocytosis by HS diluted 1/10 in presence/absence of sub-inhibitory concentrations was measured by flow cytometry including fluorescent bacteria and a neutrophil cell line. In-vivo dose-ranging experiments with HS (dilutions 1/2–1/16) and CDN (6.25 mg/kg–100 mg/kg tid for 48 h) were performed to determine the minimal protective dilution/dose (highest survival) and the non-protective highest dilution/dose (highest mortality: HS-np dilution and CDN-np dose) over 7 days. Efficacy of CDN-np in animals pre-immunized with HS-np (combined strategy) was explored and blood bacterial clearance determined. The CDN measured protein binding was 86.9%. In-vitro, CDN significantly increased phagocytosis (vs. HS 1/10). In non pre-immunized animals, t>MIC values for CDN of ≈35% (total) and ≈19% (free) were associated with 100% survival. Significant differences in survival were found between HS-np alone (≤20%) or CDN-np alone (≤20%) vs. the combined strategy (90%, 60% and 60% for Stains 1, 2 and 3), with t>MIC (total/free) of 22.8%/14.3%, 26.8%/16.0%, and 22.4%/12.7% for Strains 1, 2 and 3, respectively. Prior to the second dose (8 h), median bacterial counts were significantly lower in animals surviving vs. dead at day 7. CONCLUSIONS/SIGNIFICANCE: In mice (CDN protein binding similar to humans) total t>MIC values of ≈35% (≈19% free) were efficacious, with a decrease in the required values in pre-immunized animals. This reinforces that immunoprotection to overcome resistance may provide lifesaving strategies. Public Library of Science 2010-08-10 /pmc/articles/PMC2919394/ /pubmed/20706584 http://dx.doi.org/10.1371/journal.pone.0012041 Text en Cafini et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Cafini, Fabio Yuste, Jose Giménez, Maria-Jose Sevillano, David Aguilar, Lorenzo Alou, Luis Ramos-Sevillano, Elisa Torrico, Martha González, Natalia García, Ernesto Coronel, Pilar Prieto, Jose Enhanced In Vivo Activity of Cefditoren in Pre-Immunized Mice against Penicillin-Resistant S. pneumoniae (Serotypes 6B, 19F and 23F) in a Sepsis Model |
title | Enhanced In Vivo Activity of Cefditoren in Pre-Immunized Mice against Penicillin-Resistant S. pneumoniae (Serotypes 6B, 19F and 23F) in a Sepsis Model |
title_full | Enhanced In Vivo Activity of Cefditoren in Pre-Immunized Mice against Penicillin-Resistant S. pneumoniae (Serotypes 6B, 19F and 23F) in a Sepsis Model |
title_fullStr | Enhanced In Vivo Activity of Cefditoren in Pre-Immunized Mice against Penicillin-Resistant S. pneumoniae (Serotypes 6B, 19F and 23F) in a Sepsis Model |
title_full_unstemmed | Enhanced In Vivo Activity of Cefditoren in Pre-Immunized Mice against Penicillin-Resistant S. pneumoniae (Serotypes 6B, 19F and 23F) in a Sepsis Model |
title_short | Enhanced In Vivo Activity of Cefditoren in Pre-Immunized Mice against Penicillin-Resistant S. pneumoniae (Serotypes 6B, 19F and 23F) in a Sepsis Model |
title_sort | enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant s. pneumoniae (serotypes 6b, 19f and 23f) in a sepsis model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919394/ https://www.ncbi.nlm.nih.gov/pubmed/20706584 http://dx.doi.org/10.1371/journal.pone.0012041 |
work_keys_str_mv | AT cafinifabio enhancedinvivoactivityofcefditoreninpreimmunizedmiceagainstpenicillinresistantspneumoniaeserotypes6b19fand23finasepsismodel AT yustejose enhancedinvivoactivityofcefditoreninpreimmunizedmiceagainstpenicillinresistantspneumoniaeserotypes6b19fand23finasepsismodel AT gimenezmariajose enhancedinvivoactivityofcefditoreninpreimmunizedmiceagainstpenicillinresistantspneumoniaeserotypes6b19fand23finasepsismodel AT sevillanodavid enhancedinvivoactivityofcefditoreninpreimmunizedmiceagainstpenicillinresistantspneumoniaeserotypes6b19fand23finasepsismodel AT aguilarlorenzo enhancedinvivoactivityofcefditoreninpreimmunizedmiceagainstpenicillinresistantspneumoniaeserotypes6b19fand23finasepsismodel AT alouluis enhancedinvivoactivityofcefditoreninpreimmunizedmiceagainstpenicillinresistantspneumoniaeserotypes6b19fand23finasepsismodel AT ramossevillanoelisa enhancedinvivoactivityofcefditoreninpreimmunizedmiceagainstpenicillinresistantspneumoniaeserotypes6b19fand23finasepsismodel AT torricomartha enhancedinvivoactivityofcefditoreninpreimmunizedmiceagainstpenicillinresistantspneumoniaeserotypes6b19fand23finasepsismodel AT gonzaleznatalia enhancedinvivoactivityofcefditoreninpreimmunizedmiceagainstpenicillinresistantspneumoniaeserotypes6b19fand23finasepsismodel AT garciaernesto enhancedinvivoactivityofcefditoreninpreimmunizedmiceagainstpenicillinresistantspneumoniaeserotypes6b19fand23finasepsismodel AT coronelpilar enhancedinvivoactivityofcefditoreninpreimmunizedmiceagainstpenicillinresistantspneumoniaeserotypes6b19fand23finasepsismodel AT prietojose enhancedinvivoactivityofcefditoreninpreimmunizedmiceagainstpenicillinresistantspneumoniaeserotypes6b19fand23finasepsismodel |